CytoSorbents Corporation 
Sep 21, 2020, 07:08 ET
Apart from curing the problem of ED, this drug will stay in the body for 48 hours which is increase of 12 hours extra when compared to the normal order viagra on line Cheap levitra is non-addictive both chemically and physically and hence this is an added advantage that helps most of the men to trust levitra properien amerikabulteni.com the name called as ‘Weekend pill’ and it can be taken with the help. It is the generic version of the branded drug. This pharmacy pfizer viagra 100mg It cheapest cialis amerikabulteni.com comes in three dosages which is 25mg, 50mg and 100mg and you must confirm your dose with doctor. It can affect men of all ages, becoming the common disease among the cheapest levitra urology patients.
Mr. Alessandro Pallamolla, Chief Executive Officer of Contatti Medical stated, “Contatti is a well-established company located in southern Brazil, with over 36 years of experience providing excellent solutions to the healthcare market. We could not be happier to partner with CytoSorbents and leverage our strengths in cardiac surgery, organ transplantation, and blood bank management, to help make CytoSorb a success. CytoSorb is an innovative therapy for critical care and cardiac surgery, with huge potential in Brazil, given the high incidence of heart disease and sepsis in the country. In addition, the immediate availability of CytoSorb comes at a very delicate moment during the COVID-19 crisis in Brazil. We welcome this opportunity to work with CytoSorbents and to explore together all of the possibilities in our country.”
Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, “We are pleased to announce the official registration of CytoSorb in Brazil and the launch of our partnership with Contatti Medical to distribute CytoSorb throughout the country. We are very excited to collaborate with Contatti, whose business focus parallels ours, with an extensive network within hospitals and among physicians in Brazil. Our immediate focus will be to help treat patients with life-threatening complications of COVID-19 infection, with 30,000-40,000 new coronavirus cases a day, and a total of 4.5 million total cases in the country to date, third only to the U.S. and India.”
Brazil is the 6th most populous country in the world with a population of 212 million people divided into 5 regions and 27 states. Brazil has the 9th largest global economy with a Gross Domestic Product (GDP) of $1.87 trillion (nominal). Brazil has one of the largest public healthcare systems in the world, with universal healthcare provided to most of its citizens by the Unified Health System (SUS). There are more than 6,100 public and private hospitals throughout the country, with over 40,000 ICU beds, and over 350,000 physicians.
[huge_it_slider id=”15″]About Contatti Medical
Contatti Medical is a privately-held company located in Porto Alegre, Brazil that has been importing and distributing medical devices and disposables to the Brazilian healthcare market since 1984. Contatti Medical provides added value products and services to health businesses that perform medium and high complexity procedures in the areas of cardiac surgery, organ transplantation, and blood bank management.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 65 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® has been used in more than 100,000 human treatments to date. CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease), myoglobin (trauma) and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in critically-ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances. CytoSorb has also been granted FDA Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.